TenNor Therapeutics Announces Resignation of Non-Executive Director Michael James Bakes

Bulletin Express06-05

TenNor Therapeutics (Suzhou) Limited disclosed that non-executive director Michael James Bakes resigned from the Board on 5 June 2026 owing to a change in personal job assignment. His departure also ends his role on the Board’s Remuneration and Appraisal Committee.

The resignation leaves the committee with fewer than the required three members. In line with its Articles of Association and the committee’s terms of reference, TenNor Therapeutics plans to appoint a replacement within three months of the effective date.

The Board confirmed that Mr. Bakes has no disagreement with management and that no matters related to his departure require shareholder attention. The Board expressed appreciation for his contributions during his tenure.

Post-resignation, the Board consists of: • Executive Director: Dr. Ma Zhenkun • Non-Executive Director: Dr. Song Gaoguang • Independent Non-Executive Directors: Mr. Lee Wai Kong, Albert; Dr. Ni Lin; Dr. Li Leping

Dr. Ma Zhenkun remains chairman, chief executive officer and general manager of the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180239507?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180239507","market":"hk","top_or_hot":-1,"title":"TenNor Therapeutics Announces Resignation of Non-Executive Director Michael James Bakes","media":"Bulletin Express","content":"<p>TenNor Therapeutics (Suzhou) Limited disclosed that non-executive director Michael James Bakes resigned from the Board on 5 June 2026 owing to a change in personal job assignment. His departure also ends his role on the Board’s Remuneration and Appraisal Committee.</p>\n<p>The resignation leaves the committee with fewer than the required three members. In line with its Articles of Association and the committee’s terms of reference, TenNor Therapeutics plans to appoint a replacement within three months of the effective date.</p>\n<p>The Board confirmed that Mr. Bakes has no disagreement with management and that no matters related to his departure require shareholder attention. The Board expressed appreciation for his contributions during his tenure.</p>\n<p>Post-resignation, the Board consists of:\n• Executive Director: Dr. Ma Zhenkun  \n• Non-Executive Director: Dr. Song Gaoguang  \n• Independent Non-Executive Directors: Mr. Lee Wai Kong, Albert; Dr. Ni Lin; Dr. Li Leping</p>\n<p>Dr. Ma Zhenkun remains chairman, chief executive officer and general manager of the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics Announces Resignation of Non-Executive Director Michael James Bakes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics Announces Resignation of Non-Executive Director Michael James Bakes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-05 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TenNor Therapeutics (Suzhou) Limited disclosed that non-executive director Michael James Bakes resigned from the Board on 5 June 2026 owing to a change in personal job assignment. His departure also ends his role on the Board’s Remuneration and Appraisal Committee.</p>\n<p>The resignation leaves the committee with fewer than the required three members. In line with its Articles of Association and the committee’s terms of reference, TenNor Therapeutics plans to appoint a replacement within three months of the effective date.</p>\n<p>The Board confirmed that Mr. Bakes has no disagreement with management and that no matters related to his departure require shareholder attention. The Board expressed appreciation for his contributions during his tenure.</p>\n<p>Post-resignation, the Board consists of:\n• Executive Director: Dr. Ma Zhenkun  \n• Non-Executive Director: Dr. Song Gaoguang  \n• Independent Non-Executive Directors: Mr. Lee Wai Kong, Albert; Dr. Ni Lin; Dr. Li Leping</p>\n<p>Dr. Ma Zhenkun remains chairman, chief executive officer and general manager of the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1180239507","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180239507","pubTimestamp":1780661276,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TenNor Therapeutics (Suzhou) Limited disclosed that non-executive director Michael James Bakes resigned from the Board on 5 June 2026 owing to a change in personal job assignment. His departure also...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"TenNor Therapeutics宣布非执行董事Michael James Bakes辞职","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TenNor Therapeutics (Suzhou) Limited disclosed that non-executive director Michael James Bakes resigned from the Board on 5 June 2026 owing to a change in personal job assignment. His departure also ends his role on the Board’s Remuneration and Appraisal Committee.\nThe resignation leaves the committee with fewer than the required three members. In line with its Articles of Association and the committee’s terms of reference, TenNor Therapeutics plans to appoint a replacement within three months of the effective date.\nThe Board confirmed that Mr. Bakes has no disagreement with management and that no matters related to his departure require shareholder attention. The Board expressed appreciation for his contributions during his tenure.\nPost-resignation, the Board consists of:\n• Executive Director: Dr. Ma Zhenkun  \n• Non-Executive Director: Dr. Song Gaoguang  \n• Independent Non-Executive Directors: Mr. Lee Wai Kong, Albert; Dr. Ni Lin; Dr. Li Leping\nDr. Ma Zhenkun remains chairman, chief executive officer and general manager of the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180239507","isCrawlerRequest":true}